Figures & data
Table 1 Induction–maintenance regimens included in the model
Table 2 Summary of key characteristics in the base-case model and sensitivity analyses conducted
Table 3 PFS and OS HRs and 95% CIs for first-line induction and maintenance regimens included in the model (fixed-effect network meta-analysisTable Footnote*)
Table 4 Summary of costs included in the model
Table 5 Clinical effectiveness and cost-effectiveness of first-line induction–maintenance regimens included in the model
Table 6 Costs of treatment
Table 7 Sensitivity analyses with the greatest impact on results
Figure 1 Cost-effectiveness acceptability frontier (CEAF).
Abbreviations: BSC, best supportive care; Carb, carboplatin; Cis, cisplatin; Gem, gemcitabine; Pac, paclitaxel; Pem, pemetrexed.
![Figure 1 Cost-effectiveness acceptability frontier (CEAF).](/cms/asset/767d3050-f88c-473a-adb4-c273c0532274/dceo_a_128371_f0001_c.jpg)